Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS) on Friday named Heather Rees its principal financial and accounting officer.
Atossa disclosed the news in a regulatory filing. Rees is stepping in for Greg Weaver, who resigned as chief financial officer Thursday after starting the job June 1. An Atossa spokesperson said Weaver left to take another job, and Atossa is looking for a permanent CFO.
Weaver replaced Kyle Guse, who was Atossa's CFO for more than 10 years, according to his LinkedIn page. Weaver, meanwhile, is a board member and director at the health monitoring company BioIntelliSense. The regulatory filing noted Weaver has left Atossa's board.
Rees joined Atossa in 2017 as a controller and was promoted to vice president of finance and accounting in 2021. Prior to joining Atossa, Rees spent 10 years as an independent financial consultant, working with companies such as Avalara, Getty Images and Fisher Communications.
Atossa, founded in 2009, is developing therapies aimed at breast cancer. The company, which went public in 2012, has multiple treatments in Phase 2 clinical trials. Atossa in December closed a $4.7 million investment in the cancer-focused biotech Dynamic Cell Therapies, giving Atossa a roughly 19% stake in the company.
In late September, Atossa received notice from the Nasdaq that it faces potential delisting from the exchange because its share price had closed below $1 for 30 consecutive business days. The company disclosed the notice in a regulatory filing. Atossa has six months, or until March 25, to regain compliance by having its stock close at $1 or more per share for at least 10 consecutive business days. The company's stock closed at 70 cents per share on Tuesday.
